These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19248570)

  • 1. Dalteparin as the primary low-molecular-weight heparin on a hospital formulary.
    Goldman MC
    Conn Med; 2009 Jan; 73(1):23-8. PubMed ID: 19248570
    [No Abstract]   [Full Text] [Related]  

  • 2. Antithrombotic drugs.
    Treat Guidel Med Lett; 2011 Oct; 9(110):61-6; quiz 2 p following 66. PubMed ID: 21941228
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in managing venous thromboembolism and acute coronary syndrome: case studies of the use of antithrombotic and antiplatelet therapies. Introduction.
    Haines ST
    Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S3-4. PubMed ID: 18653823
    [No Abstract]   [Full Text] [Related]  

  • 5. Antithrombotic drugs.
    Med Lett Drugs Ther; 2014 Oct; 56(1454):103-9; quiz 1 p following 109. PubMed ID: 25337986
    [No Abstract]   [Full Text] [Related]  

  • 6. Dalteparin: only protective in hepatic ischemia-reperfusion or also capable of preventing injury in liver hyperperfusion syndrome?
    Menger MD
    Crit Care Med; 2006 Jul; 34(7):2011-3. PubMed ID: 16801867
    [No Abstract]   [Full Text] [Related]  

  • 7. Antithrombotic therapy in children with venous thromboembolism.
    Yang J; Paredes N; Chan AK
    Hamostaseologie; 2009 Jan; 29(1):80-7. PubMed ID: 19151854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of lipid peroxidation and antioxidant defense in response to dalteparin therapy in acute coronary syndrome].
    Tarasov NI; Terent'eva NV; Vorontsova NL; Barbarash LS
    Klin Med (Mosk); 2004; 82(3):63-6. PubMed ID: 15114779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 2. Subcutaneous heparin is as good as low-molecular-weight heparin in the acute treatment of thrombo-embolic disease.
    Munro A; English C
    Emerg Med J; 2008 May; 25(5):287-9. PubMed ID: 18434466
    [No Abstract]   [Full Text] [Related]  

  • 10. Dalteparin--another low-molecular-weight heparin.
    Med Lett Drugs Ther; 1995 Dec; 37(963):115-6. PubMed ID: 7500910
    [No Abstract]   [Full Text] [Related]  

  • 11. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.
    Tischenko A; Gula LJ; Yee R; Klein GJ; Skanes AC; Krahn AD
    Am Heart J; 2009 Aug; 158(2):252-6. PubMed ID: 19619702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patients.
    Merino M; Richardson N; Reaman G; Ande A; Zvada S; Liu C; Hariharan S; De Claro RA; Farrell A; Pazdur R
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28688. PubMed ID: 32896942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
    [No Abstract]   [Full Text] [Related]  

  • 14. New Pediatric Indication for Dalteparin Sodium.
    Aschenbrenner DS
    Am J Nurs; 2019 Oct; 119(10):22. PubMed ID: 31567246
    [No Abstract]   [Full Text] [Related]  

  • 15. Venous thromboembolism prophylaxis and treatment in patients with cancer.
    Kakkar AK
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):416-7. PubMed ID: 18567985
    [No Abstract]   [Full Text] [Related]  

  • 16. [Initial trials give hope. Anticoagulants against cancer?].
    Hiller E
    MMW Fortschr Med; 2003 Apr; 145(14):16. PubMed ID: 15072270
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
    Merli G; Spyropoulos AC; Caprini JA
    Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Molecular-Weight Heparin Did Not Differ from Placebo in Preventing Clinically Important Deep Venous Thrombosis After Surgical Repair of Leg Fracture.
    Little MT
    J Bone Joint Surg Am; 2016 Feb; 98(4):316. PubMed ID: 26888681
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.